Russia,as well as China and North Korea,have been unveiling new weapons in the past several years
Popcorn in one hand and the ‘Red Phone’ in the other,Vladimir Putin is now watching America’s next
People walk through Santa Cruz,Jamaica,after Hurricane Melissa passed (Picture: AP)
Hurricane Melissa lashed through Jamaica turning it into a ‘disaster area’,leaving a trail of destruction behind
GOTHENBURG,Sweden,March 7,2025-- In late February,the MOI Group consortium,anchored by Met-Gün and Opus Group,was awarded the 20-year concession to inspect all vehicles (passenger cars,trucks,bus
MANCHESTER,England,March 7,2025-- As IMO Car Wash marks its 60th anniversary on March 8th,the world\'s favourite car wash is celebrating in style—dressed in its bold new blue identity and unveiling a
GUANGZHOU,China,March 7,2025-- MINISO Group Holding Limited (NYSE: MNSO; HKEX: 9896) ("MINISO","MINISO Group" or the "Company"),a global value retailer offering a variety
HONG KONG,March 6,2025-- Akeso,Inc. (9926. HK) ("Akeso" or the "Company") is pleased to announce the completion of patient enrollment for its Phase III registrational clinical tria
SHANGHAI,March 4,2025-- USHOPAL Group continues to solidify its position as the first China-based luxury beauty group to emerge on the global stage,with an acquisition strategy that focuses on strong
BARCELONA,Spain,March 5,2025-- GTS Techlabs,the technology arm ofGlobe Teleservices (GTS),a leading telecom solutioncompany,and Peacom have announced a strategic partnership at Mobile World Congress
BARCELONA,Spain,March 5,2025-- At MWC Barcelona 2025,the Broadband Development Congress (BDC),hosted by the WBBA,was a resounding success. Themed "Smarter Broadband: Investment. Innovation. Intel
PhaseIb trial to evaluate CS5001 in combination with R-CHOP as a first-line treatment for diffuse large B-cell lymphoma (DLBCL),aiming to reshape the standard-of-care landscape.
HONG KONG,March 6,2025-- Akeso,Inc. (9926. HK) ("Akeso" or the "Company") is pleased to announce the completion of patient enrollment for its Phase III registrational clinical tria